Journal article Open Access

EFFICACY AND SAFETY OF AZILSARTAN COMPARED WITH TELMISARTAN IN HYPERTENSIVE PATIENTS.

Lenka D.N.; Routray S.N.


DataCite XML Export

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="DOI">10.5281/zenodo.3365128</identifier>
  <creators>
    <creator>
      <creatorName>Lenka D.N.</creatorName>
      <affiliation>Senior Resident, Dept. of Cardiology, S.C.B.Medical College. Cuttack, Odisha, India.</affiliation>
    </creator>
    <creator>
      <creatorName>Routray S.N.</creatorName>
      <affiliation>Professor, Dept. of Cardiology, S.C.B.Medical College. Cuttack, Odisha, India.</affiliation>
    </creator>
  </creators>
  <titles>
    <title>EFFICACY AND SAFETY OF AZILSARTAN COMPARED WITH TELMISARTAN IN HYPERTENSIVE PATIENTS.</title>
  </titles>
  <publisher>Zenodo</publisher>
  <publicationYear>2019</publicationYear>
  <subjects>
    <subject>Blood Pressure Azilsartan Telmisartan.</subject>
  </subjects>
  <dates>
    <date dateType="Issued">2019-07-01</date>
  </dates>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://zenodo.org/record/3365128</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsVersionOf">10.5281/zenodo.3365127</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="https://creativecommons.org/licenses/by/4.0/legalcode">Creative Commons Attribution 4.0 International</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">&lt;p&gt;Objective: Angiotensive receptor blockers (ARBs) are very potent antihypertensive agents , Telmisartan being the prototype and most widely used.This study was undertaken to compare the efficacy and safety of Azilsartan a new ARB with Telmisartan. Material and methods : This prospective study was carried out in patients attending the Department of Medicine, SCB Medical college, Cuttack. Patients with newly diagnosed with stage I-II essential hypertension of either sex within the age group of 18?65 years with blood pressure of &amp;ge;140/90 mmHg were included in the study. Severe hypertension &amp;gt;180/110 mm of Hg, hypersensitivity to ARBs, secondary hypertension with any other etiology, pregnant women, history of Drug/ Alcohol abuse, cardiac arrhythmias were excluded. Patients who gave consent for the study were divided into 2 random groups 1 and 2 ? the first received azilsartan and the second received telmisartan. Point of control was defined as blood pressure&amp;lt;140/90 mm of Hg after initiation of therapy. Results : 180 patients were randomized into two groups. Out of 90 patients included in group 1 who received azilsartan, 4 lost for follow up. Out of 90 patients included in group 2 who received telmisartan, 5 lost for follow up. There was no significant difference between the two drugs in both mean systolic and diastolic blood pressure at 24hrs, 1 month and 3 months and 6 months. Mean diastolic blood pressure at 24 hrs was reduced more with telmisartan compared to azilsartan which is significant. Hypotension related adverse effects occurred in 3% of the patients in azilsartan group while it occurred in 8% of them in telmisartan group. Conclusion: Azilsartan is an effective blood pressure lowering drug with its safety and efficacy comparable to that of telmisartan.&lt;/p&gt;</description>
  </descriptions>
</resource>
23
15
views
downloads
All versions This version
Views 2323
Downloads 1515
Data volume 5.3 MB5.3 MB
Unique views 2323
Unique downloads 1414

Share

Cite as